Clyra Medical Technologies, a Subsidiary of BioLargo, Appoints Dr. Steven J. Kavros as Chief Medical Officer

Rhea-AI Summary

BioLargo's subsidiary, Clyra Medical Technologies, has appointed Dr. Steven J. Kavros as its new Chief Medical Officer. Dr. Kavros brings extensive experience in advanced wound healing and limb preservation, having spent over 20 years at the Mayo Clinic. He has a strong background in research, medical education, and the medical device industry. Dr. Kavros has given over 1,800 presentations at conferences and authored numerous peer-reviewed papers. His expertise includes successfully bringing multiple products to market in wound healing, limb preservation, and orthopedics. Clyra CEO Steve Harrison believes Dr. Kavros' clinical expertise and business insight will be important for the company's manufacturing and distribution plans for its Bioclynse product.

Positive

• Appointment of highly experienced Chief Medical Officer with expertise in wound healing
• Dr. Kavros brings 20+ years of experience from prestigious Mayo Clinic
• New CMO has a track record of successfully bringing medical products to market
• Appointment aligns with Clyra's plans for manufacturing and distribution of Bioclynse product

Negative

• None.

WESTMINSTER, CA / ACCESSWIRE / September 9, 2024 / BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable environmental and life sciences technologies, announced that its partially owned subsidiary Clyra Medical Technologies had appointed Dr. Steven J. Kavros as its new Chief Medical Officer.

Dr. Kavros brings a wealth of medical expertise and experience in advanced wound healing and limb preservation to his new role at Clyra. He spent over 20 years at the prestigious Mayo Clinic in Rochester, MN, where he served as Director at the Gonda Vascular Wound Healing Center, and was involved in both research and patient care. He was also deeply engaged in medical education as Associate Professor at the Mayo Clinic's Alix School of Medicine.

Dr. Kavros is also an accomplished researcher and speaker, having given over 1,800 presentations related to his research activities at national and international conferences, and lead author of numerous peer-reviewed papers centered on new medical technologies and evidence-based medicine.

In addition to his clinical and academic achievements, Dr. Kavros has a proven track record in the medical device industry, successfully bringing to market multiple products in advanced wound healing, limb preservation, and orthopedics. He has also served in leadership roles at EPIEN Medical, TEI Biosciences, Miromatrix Medical, and Innovacyn.

Dr. Kavros earned a bachelor's degree in Biology with honors and a minor in Chemistry from Rutgers University and subsequently graduated from Temple University School of Podiatric Medicine with highest honors in surgery, orthopedics, biomechanics and podiatric medicine. Dr. Kavros is also a certified wound specialist through the American Board of Wound Management, a fellow of the American College of Certified Wound Specialists, and a founding member of the American Professional Wound Care Association, where he also served as scientific chair and later as its president from 2015-2019.

Clyra CEO Steve Harrison commented "Dr. Kavros' unique blend of clinical expertise and business insight will prove invaluable to support our significant investments for at-scale manufacturing and distribution of our Bioclynse product. His skills in leadership, team building, and entrepreneurship align perfectly with Clyra's vision and goals."

About Clyra Medical Technologies, Inc.

Clyra Medical Technologies, founded on our mission of "Make Lives Better", is a healthcare company that develops and commercializes products designed to safely treat wound and skin infections and promote wound healing, while reducing the need for antibiotics.

Clyra Medical Technologies is a proud member of the BioLargo Family of Companies (www.biolargo.com). Clyra is a subsidiary of BioLargo, Inc., a publicly traded company, with the stock symbol (OTCQX:BLGO) BioLargo is a technology innovator and solutions provider focused on some of the world's most pressing human health and environmental challenges including advanced water treatment, environmental remediation, air quality control, medical technologies, and more.

About BioLargo, Inc.

BioLargo, Inc. (OTCQX: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
dennis.calvert@biolargo.com
888-400-2863

SOURCE: BioLargo, Inc.

View the original press release on accesswire.com

FAQ

Who is the new Chief Medical Officer of Clyra Medical Technologies (BLGO)?

Dr. Steven J. Kavros has been appointed as the new Chief Medical Officer of Clyra Medical Technologies, a subsidiary of BioLargo (BLGO).

What is Dr. Steven J. Kavros' background before joining Clyra Medical Technologies (BLGO)?

Dr. Kavros spent over 20 years at the Mayo Clinic, served as Director at the Gonda Vascular Wound Healing Center, and was an Associate Professor at Mayo Clinic's Alix School of Medicine. He has also held leadership roles in several medical device companies.

How might Dr. Kavros' appointment impact Clyra Medical Technologies (BLGO)?

Dr. Kavros' clinical expertise and business insight are expected to support Clyra's investments in manufacturing and distribution of their Bioclynse product, potentially driving growth and market expansion.

What specific expertise does Dr. Kavros bring to Clyra Medical Technologies (BLGO)?

Dr. Kavros brings expertise in advanced wound healing, limb preservation, medical research, and successfully bringing medical devices to market. He has given over 1,800 presentations and authored numerous peer-reviewed papers.